Neovasc Inc (NVCN) Neovasc (NASDAQ: NVCN) Announces FDA Rejection Of Neovasc Reducer Neovasc Inc. (NASDAQ: NVCN) disclosed that the FDA has rejected the Pre-Market Approval regarding its Neovasc Reducer™. FDA has assessed the Reducer for the treatment of patients with refractory angina pectoris.
